Symberix, Inc. products

Symberix is advancing a portfolio of first-in-class drug candidates for multiple adjunct and monotherapeutic indications. Our discovery platform enables precise targeting of bacteria implicated in intestinal toxicity and gastrointestinal disease. By identifying specific bacterial enzyme targets, we can develop small molecule drugs to block harmful bacterial activity without disrupting the innocuous endogenous microbiota.

A microbiome is a collection of microorganisms (and their DNA) that occupy a particular location. The "human microbiome" is composed of trillions of tiny microbes (mostly bacteria) that thrive in our mouth, on our skin, and inside our gut. An individual`s gut microbiome is a unique and diverse community of thousands of distinct bacterial species. The vast majority of these bacteria are not harmful - in fact, many are essential to human health. In recent years, the human microbiome has been identified as an essential complement to the human body. Although gut bacteria make a positive contribution to our overall health, they have also been linked to negative health outcomes and illnesses.

Trillions of microorganisms colonize the human body and play a central role in health and disease. Symbiotic drugs target bacteria to improve human health while leaving good microbes unscathed.